Endothelin (ET), a peptide synthesized by endothelial cells (EC), causes a decreased renal blood flow and glomerular filtration rate and an increased mean arterial pressure when infused in animals. In tissue culture, ET causes smooth muscle cell (SMC) proliferation and contraction by influx of extracellular calcium, which is inhibited by calcium channel antagonists. Infusion of cyclosporine (CSA) hemodynamically parallels ET action, and knowing that CSA effects EC, we hypothesize that the vasoconstrictive effects of CSA are a result of ET synthesis by EC.
Introduction
Endothelin (ET),' a 21 amino acid peptide, is known to be synthesized by endothelial cells in animals and man (1) (2) (3) . Endothelin acts upon smooth muscle cells (SMG) as well as glo-GFR, glomerular filtration rate; HVEC, human umbilical vein endothelial cells; RBF, renal blood flow; SMC, smooth muscle cells. merular mesangial cells (GMG) which contain specific ET binding sites, resulting in cellular contraction and proliferation (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Infusion of ET in animals results in vasoconstriction with a decrease in the glomerular filtration rate (GFR) and renal blood flow (RBF) , as well as an increase in the mean arterial blood pressure (MAP) (14) (15) (16) . Separate investigators have demonstrated inhibition of the vascular constrictive effects of ET by the administration ofcalcium channel blockers (17, 18) , suggesting that the constrictive effects ofET are in part calcium channel dependent, the specificity of which is under investigation.
CSA, an immunosuppressive agent used widely in organ transplantation, has similar hemodynamic properties of ET (19) . Upon infusion of CSA into animals, a decrease in the GFR and RBF occurs along with an increase in the MAP, contributing to diminished renal function (20) . Calcium channel blockers have been used to decrease the degree of acute tubular necrosis and diminished renal function induced by CSA in transplanted allografts (21, 22 ).
Due to the parallel hemodynamic effects of CSA and ET upon SMC, we hypothesized that CSA may induce endothelin synthesis by endothelial cells which in turns acts upon vascular SMC. Also, knowing that the hemodynamic effects ofboth ET and CSA are somewhat blunted by the use of calcium channel blockers, we further hypothesized that if CSA stimulates the synthesis of ET, then the concomitant administration of calcium channel blockers may inhibit the SMC effects in the CSA recipient.
Methods
Tissue culture. Human umbilical vein endothelial cells (HVEC) were grown using standard techniques (23 Both the RIA kit used to measure ET and the anti-ET antibody were purchased from Peninsula Laboratories, Belmont, CA. The crossreactivity of measured human ET using this kit is 100% of ET-1, and 7% with ET-2 and -3 each, while the anti-ET antibody preparation is 100% cross-reactive with human ET-1, -2, and -3.
First passage HVECs were plated in duplicate wells at a density of 25,000 cells per well in 24-well plates and allowed to grow to confluency (7-8 d) as determined by observation using a Nikon inverted microscope. At the time of confluency, the media was changed to 200 ul of media containing CSA in cremophor or equal concentrations of cremophor alone at concentrations of 0, 50, 100, 200, 300, 400, and 500 ug/liter. These concentrations were chosen due to the range of therapeutic levels of CSA used clinically. After 24 h of incubation, the supernatants were removed and assayed for the presence of ET. This experiment was repeated on two separate occasions and the data is a summary of all three assays.
Next, we repeated the initial experiments incubating confluent HVECs with 200 ul of media containing CSA at the previously described dosages, along with cycloheximide (10 Mg/ml) for inhibition of protein synthesis. After 24 h ofincubation, each supernatant was separately assayed for the presence of ET. As in the first set ofexperiments, these experiments were repeated on two separate occasions and the data is a summary of all three assays.
The initial experiment was again repeated and the media from CSA-treated HVEC (conditioned media) after 24 h of incubation was removed. 100 ul of conditioned media was combined with 100 g1 (40, 000) ofHSMC and 50 ild of[3H]thymidine (20 .Ci/ml) for proliferation studies as described by others (15) . This experiment was then repeated in three separate experiments in the presence of (a) anti-ET antibody (1 Il/well), (b) Verapamil (100 sg/ml), or (c) Nifedipine (10 MM). Lastly, in order to exclude proliferative effects of CSA directly upon HSMC, CSA, in media at concentrations previously described, was incubated directly with HSMC and analyzed for proliferation. As in the first set of experiments, these experiments were repeated on two separate occasions and the data is a summary of all three assays.
We next evaluated calcium channel antagonists independent of CSA to insure that these agents did not have unto themselves direct effects upon hSMC. hSMC proliferation was evaluated as previously described in the presence of the following: (a) non-CSA (i.e., 0 Mg/liter CSA concentration) containing stock media not incubated with HVEC, (b) non-CSA containing media incubated with HVEC for 24 h, (c) non-CSA containing media incubated with HVEC for 24 h containing Verapamil, or (d) Nifedipine. The concentration of calcium channel antagonists were as previously described. Each experiment was run on two separate occasions and the data is a summary ofall three assays.
Finally, we looked at hSMC proliferation by an unrelated peptide to determine the specificity ofthe anti-ET antibody. In these experiments, parallel wells of [3H]thymidine-labeled hSMC were incubated in the presence and absence of 5 ng/ml of PDGF and analyzed for proliferation. These experiments were repeated in the presence of the anti-ET antibody at concentrations of 1 ul/well. Each experiment was run on two separate occasions and the data is a summary of all three assays.
All incubations were carried out in duplicate and statistical significance was determined using the Student's t test at P < 0.01. Where applicable, the data is presented as the mean±SEM.
Results Fig. 1 demonstrates a CSA dose-dependent increase of ET in the HVEC supernatants as compared with their basal synthesis (P < 0.01). The maximum synthesis of ET is 75% above basal levels resulting in a peak concentration of75±3.2 mmol, which is in the range of ET synthesis reported by Chabrier et al. from unstimulated HVEC (17) . Cremophor alone incubated with confluent HVEC failed to result in ET synthesis (P < 0.01).
Coincubation of CSA with cycloheximide resulted in di- 1 ). This is compared with the concentration ofET of 75% above basal at 500 /Ag/liter of CSA alone (P < 0.01).
Conditioned media from the HVECs incubated with the CSA resulted in hSMC proliferation in a dose-dependent manner, whereas the direct incubation of CSA with hSMC resulted in no proliferation above basal levels (P < 0.01, Fig. 2 ). The conditioned media of the high dose CSA resulted in proliferation 1 14% above basal levels (P< 0.01). The degree ofproliferation was diminished at all CSA concentrations of the conditioned media with the coincubation of a specific ET antibody (P < 0.01, Fig. 2 ).
Separate coincubation of Verapamil and Nifedipine with hSMC and condition media resulted in inhibition ofproliferation similar to that seen with the coadministration of the anti-ET antibody (P < 0.01, Fig. 3 ).
Comparison of hSMC proliferation by non-CSA containing media incubated with HVEC in the presence or absence of calcium channel antagonists failed to result in any statistical difference in hSMC proliferation (Fig. 4 ). Yet, comparison of HVEC-incubated media versus stock media did result in a significant increase in hSMC (P < 0.01, Fig. 4 ).
Incubation of PDGF resulted in significant proliferation of hSMC as compared with baseline (P < 0.01), which was unaffected by the presence of anti-ET antibody (Table I) . while the chronic use of CSA may lead to progressive and nonreversible renal failure (27, 28) .
This vasoconstrictive effect of CSA does not totally explain the end result of irreversible loss of glomerular flow and localized thrombosis that may occur with chronic CSA administration (29, 30 (36) . This may be due to increased release of Factor VIII by endothelial cells, for Factor VIII levels have been shown to be increased in renal transplant patients receiving CSA (37) .
Thus, this combination ofvasoconstriction as well as direct effect of CSA upon vascular endothelial cells may additively result in the Shwartzman-like effect upon glomeruli (29, 30 The peptide endothelin has been found to be synthesized by endothelial cells derived from animals and humans (1) (2) (3) . In tissue culture experiments, ET binds to specific binding sites on smooth muscle cells as well as glomerular mesangial cells resulting in proliferation and contraction (4, 11, 12) .
Due to its known vasoconstrictive effects, ET, as a causative agent in acute renal failure, has been suggested based on known hemodynamic animal data (38) . Following this hypothesis in the area of transplantation, it has been speculated that ET is a contributor to the mechanism of CSA nephrotoxicity (39) The etiology ofthe vasoconstrictive effects ofCSA has been shown in animal experiments to be due to the presence of ET and its subsequent effect upon vascular SMC (26, 40) . In these studies, the vasoconstriction of CSA is reversed or prevented with either the coadministration or pretreatment with an antibody specific to ET. The applicability to human tissue is yet to be determined, for it is recognized that endothelial cells from animals and humans respond differently to identical stimuli (41, 42) . Our findings of basal ET synthesis by HVEC that is increased with CSA provocation is supported by work of separate investigators. Clozel and Fischli have shown that ET is present in the supernatants of unstimulated HVEC (3), while Grieff et al. reported that plasma ET levels are increased in renal transplant recipients relative to the administration of CSA (43) . Grieffet al. suggest that the mechanism of the vasoconstrictive effects of CSA is stimulation of vascular endothelial cells to synthesize ET, which in turn acts upon the perivas- (44) and may possibly increase binding sites in other cells as well. Therefore, from these in vivo as well as in vitro studies, it is demonstrated that HVEC can synthesize ET, which is present in rodents as well as humans who receive CSA. Further, these animal studies reveal diminished RBF secondary to CSA, which is reversed with the coadministration of a specific antibody to ET (26, 40) .
The use of CSA in recent renal allograft transplants results in a reversible form ofrenal insufficiency that is improved with the use of a calcium channel antagonist (21, 22) . The prevention of posttransplantation ischemia by coadministration of a calcium channel antagonist may be partially explained by what is known ofET's effect upon vascular smooth muscle cells. The mechanism of action of ET to induce constriction of SMC involves influx of extracellular calcium (45) . Conflicting studies indicate that the constrictive effects of ET upon SMC may be inhibited by calcium channel antagonists such as Verapamil or Nitrendipine, while other calcium channel antagonists such as Nifedipine or Diltiazem may have little effect (7, 17) . This is further borne out in studies with Nicardipine. This dihydropyridine-sensitive calcium channel antagonist has been shown by some investigators to affect extracellular calcium influx into rodent SMC in response to ET stimulation, while other investigators are in disagreement (4, 18) . This conflict may be due to methodologic or species variations.
Nitrendipine, used in clinical trials, as well as the other calcium channel antagonists available for clinical use (Verapamil, Nifedipine and Diltiazem) have each been shown to be effective for the use ofhypertension as well as renal perfusion in the transplanted renal allograft (46, 47) . Therefore, while calcium channel antagonists may have various responses to ET's effect upon SMC, clinically available calcium channel antagonists each appear to be useful for the treatment ofhypertension and diminished RBF that is clinically evident in recipients of CSA (21, 22, 47) . This conflict between the clinical and in vivo effects of calcium channel antagonists may be due to hemodynamic effects of CSA other than that induced by ET. Other explanations include species as well as methodologic variations that require further investigation.
This study demonstrates that ET is present in the supernatants ofCSA-stimulated HVEC in a CSA dose-dependent manner. The presence of ET appears to be an effect of synthesis as opposed to cytotoxicity, for ET is not found in the supernatants ofCSA-stimulated HVEC in the presence ofa protein synthesis inhibitor.
Knowing that ET stimulates SMC proliferation and contraction, we have demonstrated that ET present in the supernatants of CSA-stimulated HVEC induces hSMC proliferation. This effect is not a function of CSA upon hSMC, for these experiments show that no proliferation occurs when CSA is directly incubated with hSMC. Further, this study demonstrates that in the presence of a specific anti-ET antibody no proliferation occurs, supporting the hypothesis that the proliferative effect of the CSA-stimulated HVEC is from ET. To ensure that anti-ET antibody does not have specific proliferative inhibitory effects upon hSMC regardless ofthe cause ofproliferation, platelet-derived growth factor (PDGF) was incubated with hSMC to induce proliferation. Comparing PDGF-induced proliferation in the presence or absence ofanti-ET antibody, no significant difference in proliferation occurred. Therefore, the inhibition ofconditioned media-induced hSMC proliferation by an anti-ET antibody appears to be specific to ET present in the conditioned media, thus supporting our hypothesis.
Calcium channel antagonists have been shown to inhibit ET-induced SMC proliferation and contraction (8) . These studies support our interpretation that ET is present from CSAstimulated HVEC which subsequently induces hSMC proliferation. In the presence of calcium channel antagonists, hSMC proliferation from conditioned media is inhibited. We agree with Wallnofer et al. that this inhibition is not ET specific, yet more likely speaks to the mechanism of action of ET upon SMC (8) . The suggestion that ET is an endogenous calcium channel agonist that can be specifically inhibited by calcium antagonists is tempting yet has been found not be valid. The calcium channel antagonist effect is parallel to that of other SMC mitogens (e.g., norepinephrine or PGF2 alpha) whose actions upon SMC also can be inhibited by calcium channel antagonists.
The findings presented here support the role of ET as a mediator of vasoconstriction with resulting hemodynamic effects due to CSA administration. The role of calcium antagonists as an approach to diminishing immediate posttransplantation renal allograft dysfunction is supported by our study, yet the mechanism ofenhancing RBF by calcium channel antagonists may be due to a multitude of causes including ET-induced SMC constriction. Further studies are needed in order to identify other mediators of changes in renal hemodynamics. This study, in consort with others, may contribute to the further understanding of CSA-induced vasculopathy and hypertension, which may in turn result in specific ET as well as other antagonists for the prevention or reversibility ofthese problematic complications of CSA.
